Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form
Reexamination Certificate
2007-06-26
2007-06-26
Azpuru, Carlos A. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
C423S400000, C423S423000, C423S427000, C423S430000, C423S434000, C423S435000
Reexamination Certificate
active
10201303
ABSTRACT:
The present invention provides a pharmaceutical composition for application to the mucosa to be used in drug therapy comprising a water-insoluble and/or water-low soluble substance, a medicament, and an aqueous medium, and having an osmotic pressure of less than 290 mOsm. This composition is superior over conventional pharmaceutical compositions for application to the mucosa, due to efficient and high permeability to the blood at the mucosa. The present invention further provides a pharmaceutical composition for application to the mucosa comprising a hemostatic agent and a medicament. This composition is superior over conventional pharmaceutical compositions for application to the mucosa, due to permeability and retentivity at the mucosa.
REFERENCES:
patent: 4271143 (1981-06-01), Schoenwald et al.
patent: 4613500 (1986-09-01), Suzuki et al.
patent: 4615697 (1986-10-01), Robinson
patent: 4988512 (1991-01-01), Azria
patent: 5147654 (1992-09-01), Place et al.
patent: 5179079 (1993-01-01), Hansen et al.
patent: 5188826 (1993-02-01), Chandrasekaran et al.
patent: 5192535 (1993-03-01), Davis et al.
patent: 5200195 (1993-04-01), Dong et al.
patent: 5281580 (1994-01-01), Yamamoto et al.
patent: 5340572 (1994-08-01), Patel et al.
patent: 5393773 (1995-02-01), Craig et al.
patent: 5474764 (1995-12-01), Patel et al.
patent: 5474768 (1995-12-01), Robinson
patent: 5733569 (1998-03-01), Azia et al.
patent: 5869096 (1999-02-01), Barclay et al.
patent: 5942242 (1999-08-01), Mizushima et al.
patent: 5976573 (1999-11-01), Kim
patent: 2107587 (1992-10-01), None
patent: 1327314 (1994-03-01), None
patent: 2164624 (1995-01-01), None
patent: 2268140 (1998-04-01), None
patent: 2278025 (1998-07-01), None
patent: 0 496 308 (1992-07-01), None
patent: 496 308 (1992-07-01), None
patent: 0781546 (1996-12-01), None
patent: 209 247 (1994-04-01), None
patent: 59-130820 (1984-07-01), None
patent: 60-224616 (1985-09-01), None
patent: 63-303031 (1988-12-01), None
patent: 63-303931 (1988-12-01), None
patent: 2-262526 (1990-10-01), None
patent: 6-172199 (1994-06-01), None
patent: 7-188059 (1995-07-01), None
patent: 8-217678 (1996-08-01), None
patent: 9-25238 (1997-01-01), None
patent: 9-235220 (1997-09-01), None
patent: 63-166832 (1998-07-01), None
patent: 88106305 (1999-04-01), None
patent: 112102979 (1998-11-01), None
patent: 11829 (2000-12-01), None
patent: WO 92/14473 (1992-09-01), None
patent: WO 97/01337 (1997-01-01), None
patent: WO 97/31626 (1997-09-01), None
patent: WO 98/00178 (1998-01-01), None
Sax's Dangerous Properties of Industiral Materials (10thEdition) vols. 1-3, Lew, Richard J., Sr, John Wiley & Sons, 2000.
Merck Index, “polysorbate 80”, 1989.
Abstract—“Nasal absorption of propranolol from different dosage forms by rats and dogs” J Pharm Sci Dec. 1980; 69;(12): 1411-3.
Abstract—“Nasal absorption of testosterone in rats” J Pharm Sci Sep. 1984; 73(9): 1300-1.
Abstract—“The time of onset of action of sublingual nitroglycerin in exercise-induced angina pectoris. A methodological study” Eur Hear J Jul. 1985; 6(7): 625-30.
Abstract—“Intranasal delivery of nicardipine in the rat” J Pharm Sci Jan. 1986; 75(1):44-6.
Abstract—“Comparison of the metabolism of diltiazem following percutaneous, subcutaneous, oral and intravenous administration.” Drug Des Deliv Nov. 1986; 1(2):151-6.
Abstract—“Comparison of bioavailability in man of tamoxifen after oral and rectal administration” J Pharm Pharmacol Dec. 1986; 38(12): 888-92.
Abstract—“Absolute bioavailability of hydromorphone after peroral and rectal administration in humans: saliva/plasma ratio and clinical effects” J Clin Pharmacol Sep. 1987; 27(9): 647-53.
Abstract—“Pharmacodynamics of acute intranasal administration of verapamil: comparison with i.v. and oral administration.” Biopharm Drug Dispos Oct.-Dec. 1985; 6(4): 447-54.
Abstract—“Absolute bioavailability of hydromorphone after peroral and rectal administration in humans: saliva/plsma ration and clinical effects.” J Clin Pharmacol Sep. 1987; 27(9): 647-53.
Abstract—“Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects.” Biopharm Drug Dispos Mar.-Apr. 1988; 9(2): 187-99.
Abstract—“Pharmacokinetics of bioavailability of hydromorphone: effectof various routes of administration.” Pharm Res Nov. 1988; 5(11): 718-21.
Abstract—“Nasal absorption of 17-alpha-ethinyloestradiol in the rat.” J Pharm Pharmacol Mar. 1989; 41(3): 214-5.
Abstract—“Nasal absorption of tetraethylammonium in rats.” Arch Int Pharmacodyn Ther Nov.-Dec. 1989; 302:7-17.
Abstract—“Pharmacokinetic study of neostigmine after intranasal and intravenous administration in the guinea pig.” Drugs Exp Clin Res 1990; 16(11):575-9.
Abstract—“Asthma therapy: present trends and future prospects.” Compr Ther Mar. 1990; 16(3):12-6.
Abstract—“Transdermal nitroglycerin systems: methods for comparison.” Clin Ther May-Jun. 1991; 13(3): 361-7.
Abstract—“Intranasal absorption of physostigmine and arecoline.” J Pharm Sci Aug. 1991; 890(8):750-1.
Abstract—“A ocmparative evaluation of two transdermal nitroglycerin delivery systems: Nitro-Dur versus Transderm-Nitro. The collaborative Investigation Group.” Clin Ther Sep.-Oct. 1991; 13(5): 545-9.
Abstract—“Pharmacokinetics and bioavailability of papaverine HCI following intravenous, peroral, rectal, vaginal, topical and buccal administration in beagle dogs.” Biopharm Drug Dispos Oct. 1991; 12(7): 537-46
Abstract—“Pharmacokinetics and bioavalability of papaverine HCI after intravenous, intracorporeal and penis topical administration in beagle dogs.” Method Find Exp Clin Pharmacol Jun. 1992; 14(5): 373-8.
Abstract—“Enhanced absorption of bumetanide from suppositories containing weak acids in rabbits.” Biol Pharm Bull Mar. 1993; 16(3): 263-7.
Abstract—“Studies on the nasal absorption of gentamycin.” Chung Hua Erh Pi Yen Hou Ko Tsa Chih 1994; 29(3): 134-6.
Abstract—“Pharamacokinetics and endometrial effects of vaginal administration of mocronized progesterone in an oil-based solution to postmenopausal women.” Fertil Steril Apr. 1996; 65(4): 860-2.
Abstract—“Colonic mucus, smoking and ulcertavie colitis” Ann R. Coll Surg Engl Mar. 1996; 78(2):85-91.
Abstract—“Studies on the response of nitroglycerin oral spray compared with sublingual tablets for angina pectoris patients with dry mouth. A multicenter trial.” Arzneimittelforschung Feb. 1997; 47(2); 128-31.
Abstract—“Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients.” J Natl Cancer Inst Apr. 15, 1998; 90(8):611-6.
Machida Minoru, et al. “Effects of Surfactants and Protease Inhibitors on Nasal Absorption of Recombinant Human Granulocyte Colony-Stimulating Factor (rhG-CSF) in Rats” Biol. Pharm. Bull 17(10) 1375-1378 1994.
Nomura Hideaki, et al. “Effects of a Dosing Solution on the Nasal Absorptionof Non-glycosylated Recombinant Human Granulocyte Colony-Stimulating Factor in Rats” Biol. Pharm. Bull 19(10) 1490-1493 1996.
European Search Report.
New Zealand Examination Report.
Bauer K.H. et al. Pharmazeutische Technologie, Georg Thieme Verlag, Stuttgart, 3rded., p. 239.
Dictionary of Food Additives, 1stedition, p. 49-50 (1994), and partial translation.
Dictionary of Food Additives, 1stEdition, (1994), pp. 36-37.
Communication from Ukraine Patent Office dated Nov. 3, 2005, App. No. 2000010301/861M.
Textbook of Pharmacology, 2ndedition, p. 319-320 (1987), and partial translation.
Japanese Office Action.
European Patent Office—Office Action.
Widdicom
Kawabe Hiroyuki
Kinoshita Wataru
Nishibe Yoshihisa
Azpuru Carlos A.
Sughrue & Mion, PLLC
Teijin Pharma Limited
LandOfFree
Pharmaceutical composition for application to mucosa does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical composition for application to mucosa, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition for application to mucosa will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3869565